英诺特: 董事会薪酬与考核委员会关于公司2025年限制性股票激励计划（草案）的核查意见

Core Viewpoint - The board of directors' remuneration and assessment committee of Beijing Innotech Biotechnology Co., Ltd. has reviewed and approved the draft of the 2025 restricted stock incentive plan, confirming the company's eligibility to implement the plan under relevant laws and regulations [1][2][3]. Summary by Sections Eligibility and Compliance - The company meets the qualifications for implementing the stock incentive plan, having no negative audit opinions or internal control issues in the last fiscal year, and has not violated profit distribution regulations in the past 36 months [2][3]. - The incentive plan does not include independent directors or supervisors, and all incentive objects meet the conditions set forth in the relevant regulations [3]. Disclosure and Approval Process - The company will publicly disclose the names and positions of the incentive objects for at least 10 days before the shareholders' meeting, and the remuneration committee will provide a review opinion on the incentive object list five days prior to the meeting [3]. - The plan's details regarding the granting and vesting of restricted stocks comply with legal regulations and do not harm the interests of the company or its shareholders [3]. Conclusion - The remuneration and assessment committee unanimously agrees to the implementation of the 2025 restricted stock incentive plan, which aims to align the interests of management and shareholders, thereby enhancing operational efficiency and supporting sustainable development [3].